• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Minerva Neuroscie (NQ: NERV )

    2.310 -0.050 (-2.12%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Minerva Neuroscie

    Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Inc. (NASDAQ: NERV) Near the Top of Equities by Percentage Gain on 6/28
    Via Investor Brand Network
    Minerva Neurosciences Inc. (NASDAQ: NERV) Leading the Way in Monday Trading Based on Percentage Gain
    Via Investor Brand Network
    Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
    Company to host conference call today at 8:30 a.m. ET 
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
    Management to Host Conference Call 
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    FDA grants appeal and files NDA 
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
    Company to Host Conference Call Today at 8:30 a.m. ET 
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
    Management to Host Conference Call 
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
    EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Retirement
    Exposures Pension Product Safety
    Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
    Company To Host Live Webcast Today at 8:30 a.m. ET 
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    5 Best Performing Micro-Cap Stocks Through the First Half of 2022
    The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices 
    Via Spotlight Growth
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.